CASE REPORTS

Hyperferritinaemia in the absence of iron overload

J D Arnold, A D Mumford, J O Lindsay, U Hegde, M Hagan, J R Hawkins

Abstract

Background—Serum ferritin is normally a marker of iron overload. Ferritin genes are sited at chromosomes 19 and 11. Regulation of ferritin synthesis involves an interaction between an iron regulatory protein (IRP) and part of the ferritin mRNA designated the iron regulatory element (IRE). A disorder of ferritin synthesis resulting in hyperferritinaemia in the absence of iron overload has been described recently.

Patients and methods—Hyperferritinaemia in the absence of iron overload was detected in a patient who was investigated for possible haemochromatosis. Serum iron, transferrin saturation, and ferritin concentration were studied in 11 members of this patient's family from three generations. Eight members had DNA samples analysed by direct cycle sequencing of the 5' untranslated region of the L ferritin gene.

Results—Six of the family members studied had serum ferritin concentrations greater than 900 µg/l. However, serum iron and transferrin saturation were normal in these subjects who all had evidence of cataracts. Three affected family members who had genetic studies of the L ferritin gene on chromosome 19 had an A to G point mutation which was not found in unaffected members.

Conclusions—There was complete concordance between a mutated IRE, cataracts, and hyperferritinaemia in three generations of this family. This family study confirms the finding that hereditary hyperferritinaemia in the absence of iron overload is an autosomal dominant inherited disorder.

(Gut 1997; 41: 408–410)

Keywords: ferritin; hyperferritinaemia; hereditary haemochromatosis; cataract; iron overload

The iron storage protein ferritin is synthesised in the liver and different proportions of the component L (19 kDa, light) and H (21 kDa, heavy) subunits give rise to isoferritins with tissue specific distributions. The L ferritin and H ferritin genes are sited at chromosomes 19 and 11, respectively.

Transferrin is the main iron transport protein. Cellular iron homeostasis is maintained by regulation of ferritin synthesis in coordination with transferrin receptor expression. Ferritin synthesis can also be stimulated as part of an acute phase response by cytokines such as tumour necrosis factor α and interleukin 1α.

Regulation of ferritin synthesis involves an interaction between an iron binding protein termed the iron regulatory protein (IRP) and the ferritin mRNA. IRP contains an iron–sulphur complex and in iron deficient cells it functions as an RNA binding protein; in iron replete cells it functions as an aconitase, an enzyme in the Krebs cycle.

A constant region of the mRNA molecule, termed the iron responsive element (IRE), binds with IRP. The resultant IRE–IRP complex inhibits ribosomal binding to mRNA and prevents translation of the ferritin coding sequence. A critical CAGUGU sequence within IRE is important for binding with IRP.

When there is iron overload, as in hereditary haemochromatosis, the IRE–IRP inhibitory system is suppressed and ferritin synthesis is increased. When this form of iron storage is saturated, iron is deposited as haemosiderin in tissue.

Relatives of patients with hereditary haemochromatosis may have elevated serum ferritin values without clinical evidence of tissue iron deposition. In hereditary haemochromatosis about 83% of affected individuals have a mutated gene on chromosome 6 designated the HLA-H gene.

We report on a family with high serum ferritin values associated with early onset cataracts. Affected family members showed no clinical evidence of hereditary haemochromatosis or iron overload.

<table>
<thead>
<tr>
<th>Family member</th>
<th>Serum ferritin (µg/l)</th>
<th>Transferrin saturation</th>
<th>Cataract</th>
</tr>
</thead>
<tbody>
<tr>
<td>I1</td>
<td>938</td>
<td>18</td>
<td>Yes</td>
</tr>
<tr>
<td>I2</td>
<td>1449</td>
<td>17</td>
<td>Yes</td>
</tr>
<tr>
<td>I1</td>
<td>1420</td>
<td>22</td>
<td>Yes</td>
</tr>
<tr>
<td>I4</td>
<td>988</td>
<td>17</td>
<td>Yes</td>
</tr>
<tr>
<td>H1</td>
<td>1452</td>
<td>26</td>
<td>Yes</td>
</tr>
<tr>
<td>H1</td>
<td>902</td>
<td>37</td>
<td>Yes</td>
</tr>
<tr>
<td>I2</td>
<td>37</td>
<td>21</td>
<td>No</td>
</tr>
<tr>
<td>H2</td>
<td>49</td>
<td>NA</td>
<td>No</td>
</tr>
<tr>
<td>H2</td>
<td>15</td>
<td>16</td>
<td>No</td>
</tr>
<tr>
<td>H3</td>
<td>19</td>
<td>NA</td>
<td>No</td>
</tr>
</tbody>
</table>
A 25 year old woman was referred to the gastroenterology clinic for investigation of possible haemochromatosis following the detection of raised serum ferritin at 1420 µg/l. She was born with cerebral palsy and complained of tiredness and brittle nails. She normally attends a learning disability clinic and since her symptoms suggested anaemia, haemoglobin and ferritin were measured. The unexpected ferritin result had prompted referral to our gastroenterology clinic. She had a history of cataracts, as did several members of her family. She was found to have a raised serum ferritin on three separate occasions despite normal haemoglobin, liver and renal function, and acute phase reactants (serum ferritin was measured using a standard solid phase, two site chemiluminescent immunometric assay (Immulite)). Her karyotype was normal and HLA haplotype was A2B44. Initial screening investigations in other family members revealed that her mother (I1) and her maternal aunt (I2) had notably elevated serum ferritin with no other markers of iron overload (table 1 and fig 1).

Liver biopsies on these two family members (I1 and I2) were done to examine for tissue iron overload. These showed no evidence of excess iron. All three family members (I1, I2, and II1) had one unit of blood each venesectioned on successive weeks. They developed iron deficiency anaemia with reduced serum iron but continued to have raised serum ferritin concentrations.

Three other family members (fig 1 and table 1) also had raised ferritin values. Blood samples from family members were analysed for genetic mutation within the L ferritin IRE.

**Case report**

A 25 year old woman was referred to the gastroenterology clinic for investigation of possible haemochromatosis following the detection of raised serum ferritin at 1420 µg/l. She was born with cerebral palsy and complained of tiredness and brittle nails. She normally attends a learning disability clinic and since her symptoms suggested anaemia, haemoglobin and ferritin were measured. The unexpected ferritin result had prompted referral to our gastroenterology clinic. She had a history of cataracts, as did several members of her family. She was found to have a raised serum ferritin on three separate occasions despite normal haemoglobin, liver and renal function, and acute phase reactants (serum ferritin was measured using a standard solid phase, two site chemiluminescent immunometric assay (Immulite)). Her karyotype was normal and HLA haplotype was A2B44. Initial screening investigations in other family members revealed that her mother (I1) and her maternal aunt (I2) had notably elevated serum ferritin with no other markers of iron overload (table 1 and fig 1).

DNA samples were amplified with the forward and reverse primers. Amplification products were immobilised onto “Gene-Screen +” membrane (DuPont) and probed as described previously.16 The primer sequences were 5’-TGCTTAAACGGTTGTTGA-3’ (mutant specific) and 5’-TGCTTCAACGATGTTT GGA-3’ (wild type).

Direct cycle sequencing of the 5’ untranslated region of the L ferritin gene revealed that subject I2 was heterozygous for an A to G point mutation at position +40. This corresponded to position 2 of the CAGUGU motif within the L ferritin IRE. Allele specific oligonucleotide hybridisation confirmed the presence of the mutation in two further affected family members studied (subjects I1 and II1); this was absent from all of the five unaffected family members (subjects II2, II3, II6, III2, III3) who were studied.

Each family member underwent an ophthalmic examination by a consultant ophthalmologist (MH). Results were normal in those with normal ferritin levels, whereas all affected family members had anterior and posterior sutural opacities (fig 2). The older members (I1 aged 62, and I2 aged 54) also had peripheral opacities of varying extent and density. The peripheral opacities had a radial orientation and were more prominent near the equator of the lens. The appearance was as clear fluid vacuoles...
between lens fibres in the cortical zone. They did not seem to interfere greatly with visual acuity.

Discussion
This is the first report of an English family with autosomal dominant inheritance of hyperferritinemia associated with premature cataracts. Our patients had normal transferrin saturations and showed no histological evidence of increased iron deposition in the liver.

The abnormal phenotype in our family was associated with heterozygosity for an A to G point mutation in the L ferritin gene. This corresponded to position 2 of the conserved CAGUGU nucleotide motif in the mRNA IRE. This mutation was absent in unaffected family members. The base substitution in this region disrupts the site specific binding between IRE and IRP thereby reducing the suppressor influence on L ferritin mRNA translation. Increased ferritin synthesis occurs independent of cellular iron status.

Inherited hyperferritinemia without iron overload has previously been reported in three continental families, all with similar inheritance pattern to our patients. In a family study reported from Italy, hyperferritinemia was associated with a G to C substitution at position 3 of the CAGUGU IRE motif. In another report from France affected members were found to have an A to G substitution in position 2. This is an identical substitution to that in our patients.

The only clinical manifestation in these patients seems to be early onset cataracts. However, the structure of the saturnal cataracts described here differs from the pulverulent type described in the French family. Hereditary cataracts are a heterogeneous group of disorders that may result from abnormal expression of genes encoding lens specific proteins. However, it is difficult to envisage how the point mutation in the L ferritin gene could result in abnormal expression of an unrelated lens protein gene. A more likely explanation is that the cataracts in our patients represent deposits of L ferritin subunits. Serum ferritin should be measured routinely in children with developmental cataracts.

“Sunflower” cataract due to deposition of copper is a rare but recognised finding in Wilson’s disease. It is unclear as to why cataracts are common in hereditary hyperferritinemia but a rare finding in hereditary haemochromatosis. It is possible that tissue specificity of isoforms found in hereditary hyperferritinemia may be different to that in hereditary haemochromatosis.

In contrast to patients with hereditary haemochromatosis, transferrin saturation is normal in hereditary hyperferritinemia. A syndrome of non-hereditary liver iron overload in patients with modestly raised serum ferritin but normal transferrin saturation was reported recently. This disorder is distinct from both hereditary haemochromatosis and hereditary hyperferritinemia and seems to be associated with hyperlipidaemia and impaired glucose tolerance.

Transferrin saturation and serum ferritin measurements are used as screening tests for hereditary haemochromatosis, but caution should be exercised in the interpretation of raised ferritin values.

Overload

Hyperferritinaemia in the absence of iron overload

J D Arnold, A D Mumford, J O Lindsay, U Hegde, M Hagan and J R Hawkins

Gut 1997 41: 408-410
doi: 10.1136/gut.41.3.408

Updated information and services can be found at:
http://gut.bmj.com/content/41/3/408

These include:

References
This article cites 18 articles, 6 of which you can access for free at:
http://gut.bmj.com/content/41/3/408#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/